Literature DB >> 8501150

Biochemical assessment of bone formation and resorption in acromegaly.

S Ezzat1, S Melmed, D Endres, D R Eyre, F R Singer.   

Abstract

The effects of chronic GH and insulin-like growth factor-I (IGF-I) excess on bone metabolism were examined by measuring serum markers of bone formation and urine markers of bone resorption as well as vertebral bone densities in patients with active acromegaly. Fasting serum GH levels were elevated in all 27 patients (31 +/- 11 micrograms/L). Serum calcium levels were within the normal range, except in 3 of 27 (10%) patients with mild hypercalcemia. Urinary calcium excretion, however, was increased in 6 (22%) patients despite mainly normal serum PTH and 1,25-dihydroxyvitamin D levels, suggesting a direct renal GH and/or IGF-I-mediated calciuric effect. Urinary hydroxyproline/creatinine excretion was increased in all except 1 patient and correlated with plasma IGF-I levels (r = 0.49; P < 0.02; n = 22). A more specific indicator of bone collagen turnover, urinary type I collagen cross-linked N-telopeptide, was elevated in all except 1 patient and correlated with serum GH (r = 0.47; P < 0.02), IGF-I (r = 0.60; P < 0.005), and urinary hydroxyproline/creatinine excretion (r = 0.62; P < 0.001). Serum bone Gla protein (osteocalcin), a specific marker of osteoblastic activity, was also increased in 50% of the patients and correlated with urinary N-telopeptide (r = 0.47; P < 0.02), but not with serum GH or IGF-I concentrations. Trabecular bone density, as determined by quantitative computerized tomography of the lumbar spine, was increased in only 1 patient; 13 others had subnormal bone density. The results suggest that in long-standing acromegaly, osteoblastic and osteoclastic activities are increased. Vertebral trabecular bone mass is usually reduced. Urinary collagen cross-links may serve as a more specific marker of bone resorption in acromegaly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501150     DOI: 10.1210/jcem.76.6.8501150

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

Review 1.  Bone mineral density in acromegaly: does growth hormone excess protect against osteoporosis?

Authors:  I Chiodini; V Trischitta; V Carnevale; A Liuzzi; A Scillitani
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

2.  Entropy and uniformity as additional parameters to optimize the effectiveness of bone CT in the evaluation of acromegalic patients.

Authors:  Olga de Castro Dytz; Pedro de Azevedo Berger; Márcio Garrison Dytz; Bernardo Alves Barbosa; Armindo Jreige Júnior; Neysa Aparecida Tinoco Reggatieri; Arthur Disegna; Wagner Diniz de Paula; Luiz Augusto Casulari; Luciana Ansaneli Naves
Journal:  Endocrine       Date:  2020-06-10       Impact factor: 3.633

Review 3.  Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature.

Authors:  Reshma Shah; Angelo Licata; Nelson M Oyesiku; Adriana G Ioachimescu
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.

Authors:  M J Kayath; J G Vieira
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 5.  Osteosarcoma and acromegaly: a case report and review of the literature.

Authors:  G A B Lima; E M S Gomes; R C Nunes; L Vieira Neto; A P A V Sieiro; E P Brabo; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 6.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

7.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Authors:  L Dalle Carbonare; V Micheletti; E Cosaro; M T Valenti; M Mottes; G Francia; M V Davì
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

9.  Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations.

Authors:  P Legovini; E De Menis; F Breda; D Billeci; A Carteri; P Pavan; N Conte
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

10.  Bone mineral density and circulating cytokines in patients with acromegaly.

Authors:  S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.